Gemtuzumab Ozogamicin
Acute Myelomonocytic Leukemia M4
Explore 6 assets in Acute Myelomonocytic Leukemia M4 →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00895934CT.gov Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | — | Completed | — | — | — |
NCT00658814CT.gov Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT00673153CT.gov Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myelomonocytic Leukemia M4
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gemtuzumab Ozogamicin (this asset) | National Cancer Institute (NCI) | P2 | BB · 64 |
| Etoposide | Stanford University | P3 | BBB |
| Cytarabine | University of Alberta | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | ECOG-ACRIN Cancer Research Group | P3 | BBB |
| Idarubicin | University of Alberta | P3 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P3 | BBB |
| Mitoxantrone | Stanford University | P2 | BBB |
| Nivestim | Rutgers, The State University of New Jersey | P3 | BB |
+42 more in the Acute Myelomonocytic Leukemia M4 cohort
Other indications for Gemtuzumab Ozogamicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Leukemia | — | P3 | BB · 69 |
| Acute Myeloid Leukemia | — | P3 | BB · 67 |
| Myelodysplastic Syndrome | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gemtuzumab Ozogamicin in Acute Myelomonocytic Leukemia M4. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gemtuzumab-ozogamicin-acute-myelomonocytic-leukemia-m4
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →